Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers

• मुख्य लेखकों: Andreas Becker (लेखक), Emily C. Martin (लेखक), David Y. Mitchell (लेखक), Roland Grenningloh (लेखक), Andrew T. Bender (लेखक), Julien Laurent (लेखक), Harald Mackenzie (लेखक), Andreas Johne (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2020-03-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Bruton's tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling, and a rational therapeutic target for autoimmune diseases. This first‐in‐human phase I, double‐blind, placebo‐controlled trial investigated the safety, tolerability, pharmacokinetics (PK), target occ...